CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed Intravascular ultrasound-guided unprotected left main coronary artery stenting in the elderly Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Long-term effects of intensive glucose lowering on cardiovascular outcomes Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life

Review ArticleVolume 72, Issue 19, November 2018

JOURNAL:J Am Coll Cardiol. Article Link

Ejection Fraction Pros and Cons: JACC State-of-the-Art Review

TH Marwick Keywords: ejection fraction; heart failure; myocardial infarction; strain; valvular heart disease

ABSTRACT

Ejection fraction (EF) reflects both cardiac function and remodeling, and is widely recognized as a valuable diagnostic and prognostic tool. Its use in a variety of settings, ranging from heart failure and myocardial infarction to valvular heart disease, has made it a cornerstone of modern cardiology, pervading guidelines and practice. However, the development of the test was in another era, with younger patients and a lower prevalence of heart failure with preserved EF. The performance expectations of EF in the current era are also demanding-in relation to detection of subclinical LV dysfunction, and especially relating to recognition of changes in LV function on sequential testing-for example in patients taking cardiotoxic drugs. This review discusses whether the impressive evidence base for EF justifies its ongoing use in the context of newer markers of LV function, and the sophisticated questions posed by modern cardiology.